ReviewAnnals of medicine and surgery (2012)2025
Status asthmaticus and the use of ketamine nebulization and magnesium sulfate: current strategies and outcomes.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy and safety of intravenous versus nebulized magnesium sulfate for acute asthma exacerbations: an overview of systematic reviews and meta-analyses.Frontiers in medicine · 2026Pooled it
- Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA-Related Mechanisms.Journal of clinical pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review aims to systematically explore and synthesize the current literature on the efficacy and safety of ketamine nebulization and magnesium sulfate as therapeutic interventions in the management of status asthmaticus. The review evaluates clinical outcomes, administration protocols, and potential adverse effects associated with these treatments. Ketamine has proven effective in managing asthma due to its bronchodilator properties, primarily by stimulating nitric oxide and catecholamine release. Magnesium sulfate has shown benefits by interfering with calcium influx, which alleviates bronchospasm and enhances bronchodilation. Both treatments have been associated with improvements in FEV1 and peak expiratory flow rates, which improve blood oxygenation and reduce bronchospasm. Despite the promising results, more research is needed to determine the optimal dosages and administration routes for these interventions. Furthermore, current studies often do not use these treatments as first-line options, which may introduce confounding variables. Future research should focus on establishing clear protocols for the use of ketamine and magnesium sulfate in refractory acute-severe asthma and status asthmaticus. This review highlights the potential for these treatments to improve clinical outcomes when standard corticosteroid therapies are insufficient, suggesting that with appropriate dosing and consideration, they could be valuable additions to the management strategies for severe asthma exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.